AstronauTx appoints Adam Rosenberg as Chair of the Board
Esme Needham | February 5, 2026 | Appointment | | AstronauTx, chair of the board
AstronauTx has announced the appointment of Adam Rosenberg as Chair of its Board of Directors.
Rosenberg’s leadership experience includes holding the role of CEO at Aliada Therapeutics, Athenen Therapeutics, Link Medicine, Rodin Therapeutics and Teleos Therapeutics. All of these companies, like AstronauTx, specialise in neuroscience. Rosenberg was also previously founder and CEO of Sionna Therapeutics. He currently serves as CEO of RyCarma Therapeutics and chairs the boards of Seamless Therapeutics and VectorY Therapeutics.
Rosenberg brings significant expertise across the life sciences industry to his new role at AstronauTx. This includes company building, as well as responsibility for partnerships and acquisitions within global pharmaceutical and biotechnology companies. Rosenberg has also led a wide variety of company boards.
Jane Rhodes, CEO of AstronauTx, said: “Adam’s deep experience in building successful neuroscience companies and leading strategic transactions will be invaluable as AstronauTx enters its next phase of growth. His insight and leadership come at a pivotal time as we progress our programmes toward the clinic and continue to strengthen our position as pioneers developing therapeutics at the intersection of sleep physiology and neurodegenerative disease.”
Rosenberg added: “There is increasing awareness around the importance of sleep quality in relation to cognitive function and disease progression. AstronauTx’s focus on sleep as a therapeutic entry point for neurodegenerative diseases has the potential to transform how we treat Alzheimer’s and other neurological conditions.”
